Jonathan Goldman, CEO of Aptuit, explained that the API capacity expansions come thanks to a 300% annual increase in demand for its APIs and for the company’s integrated candidate-to-IND development solution.
Goldman explained that Aptuit’s strategy will allow for increased throughput of integrated development programs, as well as to deliver standalone API at 40-120 kg batch scale for early to mid-stage clinical trials.
“There is a gap in the market for high quality API at this scale, and Aptuit is delighted to serve this need,” he said.